Company intelligence / Profile preview

Hecto Healthcare

Seoul, South Korea

Ownership: Private
Development stage: Other

Overview

Hecto Healthcare produces and markets premium probiotic products (not drugs; health functional foods) including the DeSimone brand, centered on the proprietary de Simone formula. These products are recognized for intestinal and immune health enhancement in infants, children, and families, and have recently expanded internationally (notably China), partnering with a major state-run pharmaceutical distributor for local market adaptation

Therapeutic areas: GastroenterologyImmunology
Modalities: Biologic (specifically probiotic formulations)
Industry: Non-Drug Biotech

Partnerships

Sinopharm Group/Sinomedy (China) for distribution of DeSimone products

Beyond the preview

Go deeper on Hecto Healthcare.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Hecto Healthcare.

Explore the full profile